LLYLoxo Oncology, Inc.Running, no new patients
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 238 (final count)
- Started
- Mar 9, 2021
- Main results expected
- Aug 29, 2023
- Fully finished
- May 2027
- Results posted
- Mar 7, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
Measured over: Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04666038 · record last updated 2026-04-24 · checked 2026-11-09 15:36 UTC